期刊文献+

时间分辨免疫荧光法定量检测血清HBeAg/HBeAb的可行性分析 被引量:1

Feasibility analysis of quantitative detection on serum HBeAg/HBeAb by time-resolved immunofluorescence assay
下载PDF
导出
摘要 目的:探讨国产时间分辨免疫荧光法(time-resolved immunofluorescence assay,TRIFA)是否与全自动化学发光免疫分析法(automatic chemiluminescence immunoassay,CMIA)在定量检测HBeAg/HBeAb中具有同样的准确性和特异性。方法:157份来自中南大学湘雅医院感染病科门诊的HBV感染患者的血清标本,分别用CMIA和TRIFA两种方法进行HBeAg定量及HBeAg/HBeAb定性检测,并对结果进行对比分析。结果:两种方法定量检测HBeAg的直线回归方程为:Y=0.72779X–4.0551(r=0.712,P<0.001)。与CMIA比较,TRIFA检测HBeAg定性结果的灵敏度和特异性分别为89.89%和100%,两种方法诊断HBeAg符合率为94.27%。TRIFA检测HBeAb定性结果的灵敏度和特异性分别为100%和95.45%,两种方法诊断HBeAb的符合率为97.45%。结论:TRIFA在HBeAg/HBeAb定量检测上的准确性、灵敏度和特异性与CMIA基本相当,二者HBeAg/HBeAb诊断符合率高。 Objective: To determine whether time-resolved immunofluorescence assay (TRIFA) shares the similar accuracy and specificity with automatic chemiluminescence immunoassay (CMIA) in analyzing HBeAg levels in hepatitis B. Methods: A total of 157 serum samples were collected from outpatients with infection of HBV in Xiangya Hospital, Central South University. CMIA and TRIFA were used to analyze HBeAg quantitation and HBeAg/HBeAb qualitative detection, respectively. Results: The linear regression equation for the two methods was Y=0.72779X–4.0551 (r=0.712, P〈0.001). Compared with the CMIA, the sensitivity and specificity in detection of HBeAg by TRIFA were 89.89% and 100%, respectively, and the coincidence rate of HBeAg was 94.27% by two assays. Similarly, the sensitivity and specificity in detection of HBeAb by TRIFA were 100% and 95.45%, respectively. The coincidence rate was 97.45% by two assays. Conclusion: TRIFA has similar accuracy, sensitivity, and specificity with CMIA in quantitative detection of HBeAg, and their coincidence rate in detection of HBeAg/HBeAb is high.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2016年第8期852-855,共4页 Journal of Central South University :Medical Science
基金 湖南省科技厅重点研发计划(2015JC3009)~~
关键词 乙型肝炎 HBeAg/HBeAb 全自动化学发光免疫分析法 时间分辨免疫荧光法 hepatitis B HBeAg/HBeAb automatic chemiluminescence immunoassay time-resolved immunofluorescence assay
  • 相关文献

参考文献3

二级参考文献15

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2Juergen Beck,Michael Nassal.Hepatitis B virus replication[J].World Journal of Gastroenterology,2007,13(1):48-64. 被引量:55
  • 3Ayoub WS,Keeffe EB.Review article:current antiviral therapy of chronic hepatitis B[J].Aliment Pharmacol 3her,2011,34( 10):1145-1158.
  • 4Swets JA.Measuring the accuracy of diagnostic systems[J].Science, 1988,240(4857):1285-1293.
  • 5Lau GK.Current treatments for patients with IqBeAg-positive chronic hepatitis B virus infection:a comparison focusing on HBeAg seroconversion [J] .Liver Int,2010,30 (4) :512-520.
  • 6Cooksley WG, Piratvisuth T, Lee SD,et al.Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B [J].J Viral Hepat,2003, 10(4) :298-305.
  • 7. Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J.N Engl J Med,2005,352(26):2682-2695.
  • 8Fried MW, Piratvisuth T, Lau GK,et al.HBeAg and hepatitis B virus DNA as outcome predictors during therapy with pegiaterferon Alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatolog,b2008,47(2) :428-434.
  • 9Nguyen T, Desmond P, Locarnini S.Tne role of quantitative hepatitis B serology in the natural history and management of chronichepatitis B [J].Hepatol lnt,2009,3(Suppl 1):S5-S15.
  • 10Fried MW, Piratvisuth T Lau GKjet al.HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology,2008j47(2) :428-434.

共引文献203

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部